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Summary
QUESTION UNDER STUDY: Our aim was to assess
whether a novel approach of digitally facilitated, citizen-
science research, as followed by the Swiss Multiple Scle-
rosis Registry (Swiss MS Registry), leads to accelerated
participant recruitment and more diverse study popula-
tions compared with traditional research studies where
participants are mostly recruited in study centres without
the use of digital technology.
METHODS: The Swiss MS Registry is a prospective, lon-
gitudinal, observational study covering all Switzerland.
Participants actively contribute to the Swiss MS Registry,
from defining research questions to providing data (online
or on a paper form) and co-authoring papers. We com-
pared the recruitment dynamics over the first 18 months
with the a priori defined recruitment goals and assessed
whether a priori defined groups were enrolled who are like-
ly to be missed by traditional research studies.
RESULTS: The goal to recruit 400 participants in the first
year was reached after only 20 days, and by the end of
18 months 1700 participants had enrolled in the Swiss MS
Registry, vastly exceeding expectations. Of the a priori de-
fined groups with potential underrepresentation in other
studies, 645 participants (46.5%) received care at a pri-
vate neurology practice, 167 participants (12%) did not re-
port any use of healthcare services in the past 12 months,
32 (2.3%) participants lived in rural mountainous areas,
and 20 (2.0% of the 1041 for whom this information was
available) lived in a long-term care facility. Having both
online and paper options increased diversity of the study
population in terms of geographic origin and type and
severity of disease, as well as use of health care services.
In particular, paper enrolees tended to be older, more fre-
quently affected by progressive MS types and more like-
ly to have accessed healthcare services in the past 12
months.
CONCLUSION: Academic and industry-driven medical re-
search faces substantial challenges in terms of patient
involvement, recruitment, relevance and generalisability.
Digital studies and stakeholder engagement may have
enormous potential for medical research. But many digital
studies are based on limited participant information and/
or informed consent and unclear data ownership, and are
subject to selection bias, confounding and information
bias. The Swiss MS Registry serves as an example of
a digitally enhanced, citizen-science study that leverages
the advantages of both traditional medical research, with
its established research methods, and novel societal and
technological developments, while mitigating their ethical
and legal disadvantages and risks.
Trial registration number: ClinicalTrials.gov identifier
NCT02980640.
Key words: multiple sclerosis, registry, citizen science,
digitalization, technology, study design
Introduction
Academic or industry scientists who perform studies with
limited patient engagement beyond study participation tra-
ditionally drive medical research. Although this approach
has led to many notable advances, many substantial short-
comings of this framework remain (table 1). First, the
knowledge base available for patient and public health
decisions is often insufficient, because many issues rele-
vant to patients and caregivers are missing, or because pa-
tient-relevant outcomes are not considered [1, 2]. Second,
few studies include comparative effectiveness assessments
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of pharmacological or nonpharmacological interventions,
thus hampering medical decision-making [3, 4]. Third, tra-
ditional studies often apply restrictive exclusion criteria or
rely on recruitment in specialised clinical centres [5, 6].
These methods may improve the chances of finding de-
sired effects, but may endanger the generalisability of the
findings and create a lack of diversity in the study popula-
tion, frequently underrepresenting individuals who choose
to receive either care in nonspecialised outpatient settings
or no medical care at all. This is particularly problematic
for studies that address questions of disease burden such
as incidence, prevalence, health-related quality of life and
loss of years at full health, as well as questions about the
use of healthcare services.
Fortunately, recent developments in society and technolo-
gy could help to overcome some of the above challenges.
For example, patients no longer depend on healthcare pro-
fessionals for access to their own health data [7], as med-
ical tests and their interpretation become publicly avail-
able. Self-tracking devices and big-data analytics provide
individualised diagnoses or predictions of disease risks and
outcomes. Online platforms (e.g., patientslikeme, CureTo-
gether) and social media [8] invite and enable healthy peo-
ple and patients to share health data and experiences. These
social and technological developments have considerable
potential to accelerate medical research and broaden the
size and diversity of study populations [9].
However, these novel opportunities for medical research
are not without legal, ethical and methodological chal-
lenges. Biological or digital data are often amassed on
vague ethical and legal bases including unclear informa-
tion and consent procedures, unspecified purposes, unclear
data ownership and undetermined storage durations [10].
Even with informed consent, the purpose of data collection
and the sharing rules are often not fully specified at the
time of signature [10]. Additionally, the purchase and use
of patient-contributed data by third parties can often go un-
noticed by participants and the implications of this are un-
known. Finally, reliance on self-collected, unstructured pa-
tient data raises questions about the internal and external
validity of the study results [11]. Self-selection and con-
venience study samples could impair confounder control
and the implementation of measures against other validity
threats.
The Swiss Multiple Sclerosis (MS) Registry is designed
to leverage the advantages of both traditional medical re-
search and novel societal and technological developments,
while mitigating their methodological, ethical and legal
disadvantages, and risks. The aim of this article is to assess
the first 18 months of participant recruitment in the Swiss
MS Registry, which follows a novel approach of digitally
facilitated, citizen-science research. Specifically, we aimed
at assessing if participant recruitment was indeed acceler-
ated, and whether the study population was more diverse
than in research studies following more traditional ap-
proaches of participant involvement and recruitment.
Methods
Study design and goals of the Swiss MS Registry
The Swiss MS Registry is a prospective, longitudinal, ob-
servational study covering the entirety of Switzerland
(ClinicalTrials.gov identifier NCT02980640; approved for
nationwide conduct as a multicentre study by the Ethics
Committee Zurich, study number PB-2016-00894). Based
on the notion of well-aligned interests, mutual trust and
complementary expertise, the following goals were de-
fined by persons with MS, the Swiss MS Society, re-
Table 1: Advantages and disadvantages of traditional medical research, and opportunities and risks of novel approaches using societal and technological developments.
Criterion Traditional clinical research (e.g., cohort study or
clinical trial)
Novel approaches to research using digital tools and citizen
or patient engagement (e.g., patientslikeme)
1. Legal and ethical framework (+) Established by law and research community, but
often not adaptive to novel trends
(−) Still in development, currently a situation of legal and ethical
uncertainty
2. Scientifically rigorous methodology (+) Extensively developed methodology in terms of
study designs and statistical tools
(+) Can partially rely on existing methods
(−) Comprehensive methodology still in development, little guid-
ance available
3. Acceptance by medical community, regulatory
agencies and policy makers
(+) If guidance on scientifically rigorous methods is
followed
(−) Low as yet, mainly due to shortcomings listed above
4. Framework for evidence reporting and interpreta-
tion
(+) Well established and widely accepted (e.g., re-
porting guidelines)
(−) Still in development
5. Citizen science (patient involvement in study de-
sign, execution, and analysis)
(−) Often not considered (+) Core feature; strong involvement considerably enhances par-
ticipation
6. Includes multiple stakeholder views (−) Often limited (+) More flexible, strong focus on citizen and/or patient perspec-
tive
7. Patient-relevant study outcomes (−) Tendency for overreliance on clinical outcomes;
patient-reported outcomes not always considered
(+) Core feature
(−) Clinical outcomes often not available
8. Creates knowledge base for real-world questions (−) Not always given, potential overreliance on clini-
cal outcomes and highly selected study populations
(+) If well conducted, delivers more comprehensive evidence,
closer to real-life situations
9. Adaptive to novel technological trends (0) Possible, but sometimes difficult to fit into estab-
lished frameworks (e.g., online data collection tools)
(+) Core feature; can incorporate behaviour data, social media
activities, data from internet of things
10. Clearly defined target, source and study popula-
tions
(+) Often good for populations in clinical care
(−) Selection may lead to lack of external validity
(+) Often inclusive recruitment
(−) selection process not well understood
11. Risk for measurement and information biases;
data quality
(+) If well executed, manageable risk (+) Self-measurement, interpretation of own data
(−) Often patient interpreted; objective measurements sometimes
difficult; prone to information biases; difficult to implement data
quality procedures
12. Data ownership, oversight, transparent gover-
nance
(−) Unclear, patients rarely see their own data; little
strategic influence by patients (e.g., regarding study
goals)
(+) Core feature if clearly and transparently defined; comprehen-
sive inclusion of patients; study participants see their own data
(−) Uncontrolled use of participants’ data
(−) Data ownership not regulated
(+) advantage, (0) neutral, (−) disadvantage, risk
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searchers and healthcare professionals [1]: to monitor epi-
demiological trends of MS in Switzerland over time [2]; to
estimate the burden on persons with MS and families/prox-
ies; and [3] to establish a flexible network enabling inter-
and transdisciplinary, patient-centred research.
We chose a layered model that takes into account the often
long diagnostic process of MS and allows for different lev-
els of involvement by participants (fig. 1), similar to the
Amyotrophic Lateral Sclerosis Registry in the USA [12].
Layers 1 and 2 do not have any exclusion criteria and are
open to persons with MS, persons with a still uncertain di-
agnoses of MS and to family members or relatives. Infor-
mation on the Swiss MS Registry can be retrieved via a
special section on the Swiss MS Society’s webpage, where
additional information on MS in general is also available.
This integration creates synergies for both parties by con-
tent linkage and increased visitor traffic.
For data collection, a separate, independent web platform,
which is hosted by the University of Zurich, was construct-
ed. In order to gain access to this web platform and lay-
er 1, users have to create an account. In this step, interest-
ed persons deposit their contact data (name, address) and
provide information about their “role” (patient or relative).
During the user account creation, a unique identification
number is assigned to that person. The full contact data and
unique identification numbers are stored in a secured data-
base, which is kept separate from all other research data
and accessible only to defined data managers.
Layer 2 aims at determining whether persons with self-re-
ported confirmed or unconfirmed MS fulfil the eligibility
criteria for the Swiss MS Registry, in order to obtain basic
information on demography and MS status. The layer 2
questionnaire also includes teaser questions on patient-
relevant topics (e.g., alternative medicines, behavioural
changes after MS diagnosis) to spark the participant’s in-
terest in additional surveys. Layer 2 provides more time
to establish and confirm a diagnosis. This accommodates
the often long diagnostic process for MS and avoids ex-
cluding people only potentially affected by MS from the
Swiss MS Registry right away. Patients wishing to join lay-
er 2 must be at least 18 years of age and have to sign an
online informed consent form, which informs them about
the type and purpose of data collection and possible risks
and benefits of the study, as well as their rights. As part
of this agreement, patients also consent to being contacted
by members of the Swiss MS Registry data centre staff if
needed (e.g., for data clarification, retrieval of diagnosis
confirmation, or for invitations to additional substudies).
Importantly, participants also have the option to complete
the questionnaires on paper, offline. This option was cre-
ated to enable participation of those without regular use of
computers or other devices, or with impairment that makes
using the online platform too burdensome.
A confirmed diagnosis of MS or of a Clinical Isolated Syn-
drome and a signed online informed consent form are pre-
requisites for entering layer 3. The diagnosis needs to be
confirmed in writing by a neurologist, but no restriction re-
garding type of diagnostic criteria are imposed (e.g., Mc-
Donald or Poser criteria). Data collection within this layer
is much more comprehensive (see “Measurements” section
below). Finally, a subset of layer 3 participants is randomly
selected for data ascertainment based on medical records
(layer 4). The informed consent for the Swiss MS Registry
covers data collection in layers 2 to 4. Participants can con-
sent to layer 4 study modules on an opt-in basis. If pro-
vided, the layer 4 informed consent allows study nurses of
the Swiss MS Registry to visit the respective clinics and
practices and extract specific clinical information from the
medical records.
Inter- and transdisciplinary governance
The Swiss MS Registry operates in a spirit of cooperation
and mutual trust, reflected in the involvement of all rele-
vant stakeholders and voting rights through their represen-
tatives. The scientific assembly and its 20 members form
the governance body of the Swiss MS Registry and it takes
Figure 1: Layered model and type of data collection in the Swiss Multiple Sclerosis Registry.CIS = clinically isolated syndrome; MRI = magnet-
ic resonance imaging; MS = multiple sclerosis
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all strategic decisions, whenever possible by consensus.
The members are persons with MS, representatives of the
Swiss MS Society, healthcare professionals working in the
area of MS, and scientists with particular expertise in clini-
cal or community-based MS research, epidemiology or in-
formation technology. The German-, French- and Italian-
speaking parts of Switzerland, as well as diverse healthcare
settings, are all represented in the scientific assembly. The
members of the assembly have regular phone calls and
meet biannually in person. All strategic decisions, and ap-
proval of regulations, projects and publications are made
by this inter- and transdisciplinary group. Professor Jürg
Kesselring serves as the first president of the Swiss MS
Registry and chairs the scientific assembly meetings.
Each assembly member also contributes to one of three re-
search committees: a Data Committee concerned with the
operation of the registry; a Patient- and Population-based
Research Committee, and a Laboratory- and Clinic-based
Research Committee, both of which oversee and govern
the scientific parts of the Registry. The three committees
review and approve requests for Swiss MS Registry data
for research purposes. Data management and the daily op-
eration of the Swiss MS Registry are led by the Data Cen-
tre team at the Epidemiology, Biostatistics and Prevention
Institute of the University of Zurich.
Measurements
A particular challenge in studying MS is its multifaceted
manifestation. In order to comprehensively describe this
“disease with a thousand faces”, various aspects of life and
health need to be covered. The online format of the Swiss
MS Registry allows participants to interrupt the comple-
tion of questionnaires, which facilitate the comprehensive
data collection needed to address the main questions and
goals of the Swiss MS Registry. Data collected include so-
ciodemographic and family history data, as well as infor-
mation on (lifestyle) behaviours and exposures, and living
and working conditions. In addition, data on the gener-
al cultural, environmental and socioeconomic conditions
can be added, depending on where participants live. The
breadth of the Swiss MS Registry data collection goes well
beyond the clinical context and allows study questions on
burden and causes of disease, and prognostic and therapeu-
tic questions, as well as research on health services for per-
sons with MS. Layer 4 provides detailed clinical data from
medical records, which are abstracted using standardised
forms that are harmonised with data collected in the Swiss
MS cohort study.
The Swiss MS Registry closely collaborates with the Swiss
MS Cohort Study [13], a clinic-based study at eight major
Swiss MS centres. The joint databases offer opportunities
for data validation and for innovative projects combining
patient-reported Swiss MS Registry data and high quality
clinical information and bio-samples from the Swiss MS
Cohort Study through harmonised data collection and in-
formed consent for data linkage. Combining data from lay-
er 3 and 4 with data from the Swiss MS cohort allows com-
prehensive checks and validation of data from both studies
and enables continuous improvements in data quality. Fur-
thermore, the provision of regular extracts from their own
survey data allows persons with MS to report errors.
Information technology
Information technology (IT) security and data protection
are not only top priorities for the Swiss MS Registry, but
were also prime concerns for persons with MS in stake-
holder meetings. Furthermore, the flexible study design
and the fact that some persons with MS have impaired
ability to fill in lengthy online surveys impose high re-
quirements on IT infrastructure. In order to meet these de-
mands, a close collaboration with the Science IT Depart-
ment of the University of Zurich was established. After
careful evaluation of existing IT systems, a panel of IT
specialists recommended the development of a custom-
built platform with special emphasis on usability and bar-
rier freedom. This platform was developed by a team of
specialists on the basis of open-source technologies. IT
security features include, amongst others, password pro-
tection, TLS-encrypted communication and data transfers,
and strict separation of identifiable and unidentifiable data,
and were subjected to an external audit by a company spe-
cialised in IT security. The research database is hosted in a
secure environment on servers of the University of Zurich.
Already at an early planning stage, the strategic goal was
declared to be provision of relevant, individualised and
understandable feedback to participants, which greatly in-
creases study participation and commitment. The Swiss
MS Registry web platform also offers a user interface for
data collection through study forms, a diary and a dash-
board, which displays ongoing surveys and select displays
of user-specific data. Persons with MS and the Swiss MS
Society were closely involved in the design and testing of
the interface.
Statistical analysis
To address the first aim of this study – the dynamics of re-
cruitment over the first 18 months of the Swiss MS Reg-
istry – we used descriptive statistics to present the number
of participants in layers 1 to 4 and plotted the cumula-
tive number of participants against time (June 2016 to No-
vember 2017). Our hypothesis was that recruitment would
be faster for the Swiss MS Registry than in traditional re-
search studies for several reasons. First, persons with MS
themselves wished to have a registry and are therefore very
motivated to participate. Second, while the close involve-
ment of and backing by the Swiss MS Society was cru-
cial for gaining trust by key stakeholders, the society al-
so heavily promoted the Swiss MS Registry through its
news outlets. Third, access to the study through an on-
line platform within the website of the Swiss MS Soci-
ety makes participation more convenient and independent
of place and time. We compared recruitment against our
goal for recruitment for the first year of 400 participants,
which was based on prior experience from other observa-
tional longitudinal studies in more traditional clinical set-
tings in Switzerland.
The second aim of this study was to assess the diversity of
the study population, which we believe has been promot-
ed in healthcare settings, independent recruitment, through
the availability of both online and paper questionnaires,
and by the layer-based study design, which allows different
participation options and takes into account prolonged time
to diagnosis. In particular, we hypothesised that the study
population of the Swiss MS Registry would be more di-
verse than those in traditional research studies and better
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able to capture potentially underrepresented patient
groups. To this end, we defined up-front patient groups that
tend to be rarely seen in other observational MS studies.
These groups were based on the healthcare setting (prima-
ry care, neurology clinic or private practice of neurologist)
in which participants are looked after the, as well as the
place where they live. We compared various characteristics
between online participants with those who preferred pa-
per questionnaires. For this analysis, we used descriptive
statistics to assess and compare a number of characteris-
tics, such as age, sex, type of MS, use of healthcare ser-
vices or severity of symptoms for all participants and those
who used the online platform or paper form. We chose not
to use statistical tests for these comparisons since statistical
significance testing is a poor guide to interpretation of im-
portant differences between groups. For statistical analysis,
we used STATA version 13 (StataCorp LLC, College Sta-
tion, TX, U.S.A.).
Results
Recruitment within the first eighteen months
The Swiss MS Registry was launched on 25 June 2016,
when the Swiss MS Society organised the first Swiss MS
Day. Figure 2 shows the enrolment of participants from the
first day, when 160 participants joined, to 30 November
2017. The goal of 400 participants in the first year was
reached within 20 days. After this first phase, there was
a steady increase with small hikes at 3-month intervals
when the Swiss MS Society published articles on the Swiss
MS Registry (including enrolment instructions) in its news
magazine. Recruitment continued with one or two enrolees
per day up to 30 November 2017, when the total number
of participants reached 1683. Of these, 1412 completed the
layer 2 questionnaire assessment and 915 provided proof
of MS diagnosis from their treating physician (mostly neu-
rologists). Of the participants, 80% enrolled using the web-
based application whereas 20% preferred the paper ver-
sion.
Data quality and diversity of study population
At the time of analysis, 5% of all entry questionnaires were
not complete (in some instances after several reminders).
However, in the completed questionnaires, the percent-
age of missing items for key descriptor variables was low,
ranging from, for example, 0.9% on questions about fur-
Figure 2: Cumulative enrolment of participants in the Swiss MS
Registry.
ther MS cases among relatives to 5% for the year of first
symptom occurrence. Notably, these information gaps are
constantly being filled by compilation of data from addi-
tional sources (e.g., the diagnosis confirmation), by simi-
lar questions in follow-up surveys and through reporting of
corrections by participants upon receipt of individualised
data feedback.
The analysis of study population diversity was based on
the 1387 processed questionnaires of the 1412 participants
who had completed the layer 2 assessment. As shown in
table 2 (column 2), the median age was 48 years (range
18–84), the median age at onset of symptoms 32 years
(range 10–69) and the median number of years since MS
diagnosis was 9 years (range 0–57). Although there was
at the time an overrepresentation of participants from the
German-speaking part of Switzerland, all cantons were
well represented, including the French- and Italian speak-
ing regions. Of note, 40 participants (2.9%) had moved to
Switzerland relatively recently, since 2006. Moreover, 32
(2.3%) participants lived in a rural mountainous area and
20 (2.0% out of 1041 for whom this information was avail-
able) lived in a long-term care facility.
Most participants were cared for by neurologists, but, in
contrast to many other studies, many of these 645 partic-
ipants (46.5%) received care at a private neurology prac-
tice. In addition, 12% of the participants did not report any
use of healthcare services in the previous 12 months, and
20 (1.4%) participants with relapsing-remitting MS did not
receive disease-modifying treatments. Further, 94 (6.8%)
participants joined the Swiss MS Registry within 1 year of
diagnosis. Combined, these results suggest that the Swiss
MS Registry included substantial numbers of participants
who would have been unlikely to enrol in a more tradition-
al study in a clinic-based setting.
Table 2 also shows the characteristics of all participants
stratified by web-based or paper participation. Those with
online participation were around 10 years younger than
those favouring the paper forms. Moreover, participants
from German-speaking cantons tended to favour online
participation, whereas participants from French- and Ital-
ian-speaking parts were more likely to favour the paper
form. The distribution of types of MS also differed sub-
stantially between those participating online (more likely
to have relapsing-remitting MS) and those using paper
(more likely to have primary or secondary progressive
MS). This was further reflected in the burden of MS as
measured with EuroQol 5-D, which showed less impair-
ment for those participating online. Two thirds of partici-
pants were members of the Swiss MS Society, whereas the
remaining one third only received its news or used its ser-
vices, or were not connected at all with the Swiss MS So-
ciety. These results suggested that the Swiss MS Registry
study population is more diverse than in studies offering
just paper or online participation.
Discussion
This analysis showed a rapid recruitment of participants
into the Swiss MS Registry that vastly exceeded expecta-
tions. The study population was diverse and the compar-
ison of online with paper participants showed that using
both options increases the diversity of the study population
in terms of geographic origin and type and severity of dis-
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ease. Importantly, data quality appeared to be high, given
the high proportion of data completeness. Moreover, pre-
liminary analyses published on the website of the Swiss
Multiple Sclerosis Society and cross-comparisons with
other Swiss studies [14] further attest to the plausibility of
the data and the results.
There are two concurrent studies for which comparisons
in terms of the population enrolled and scientific questions
are admissible: the Swiss MS Cohort Study and the Ger-
man MS Registry [13, 15]. In the Swiss MS Cohort Study,
persons with MS are a little younger with slightly shorter
time since diagnosis, whereas in the German MS Registry
participants are of similar age but with reported more years
since diagnosis. The clinic-based setting of the Swiss MS
Cohort Study and the German MS Registry offer advan-
tages in terms of the clinical, physiological and imaging
data that can be collected, whereas the study populations
are likely to be less diverse than in the Swiss MS Registry.
As a consequence, the Swiss MS Registry complements
these other ongoing studies almost ideally. For example,
the Swiss MS Cohort Study and the German MS Registry
address more clinical questions and questions on biomark-
ers and imaging for MS, whereas the Swiss MS Registry
provides more representative data on disease burden and
the everyday life of persons with MS. In addition, since
the Swiss MS Registry spans across the healthcare system,
questions on diagnostic (from first symptoms to diagnosis)
and therapeutic pathways can be addressed.
Comparisons with other large MS studies in terms of diver-
sity of study populations are more challenging. The land-
scape of MS currently changes rapidly, and there is an in-
creasing awareness of the need to make a rapid diagnosis
and of the increasing availability of novel disease-modi-
fying treatments, both of which have a substantial impact
on the participants recruited in clinical centres. Thus, a
comparison with studies whose recruitment phase was 5 or
Table 2: Characteristics of study population enrolled in the first 18 months and who completed the layer 2 questionnaire.
All Online participation Paper participation
N 1387 1154 233
Year of birth, median (IQR) 1969
(1959; 1978)
1970
(1962; 1979)
1960
(1951; 1969)
Female sex 1007 (72.6%) 819 (71.0%) 188 (80.7%)
Region
German-speaking (incl. Rumantsch) 1134 (81.8%) 950 (82.3%) 182 (78.1%)
French-speaking 205 (14.8%) 165 (14.3%) 40 (17.2%)
Italian-speaking 48 (3.5%) 39 (3.4%) 11 (4.7%)
Nationality
Swiss 1262 (90.5%) 1044 (90.5%) 218 (93.6%)
Other 125 (9.0%) 110 (9.5%) 15 (6.4%)
Informed consent module agreements
Permission for treating physician to confirm diagnosis 1348 (97.3%) 1123 (97.3%) 225 (96.6%)
Medical record abstraction 1293 (93.2%) 1071 (92.8%) 222 (95.3%)
MS Type
Clinically isolated syndrome 59 (4.3%) 51 (4.4%) 8 (3.4%)
RRMS 885 (63.8%) 773 (67.0%) 112 (48.1%)
SPMS 215 (15.5%) 160 (13.9%) 55 (23.6%)
PPMS 149 (10.7%) 104 (9.0%) 45 (19.3%)
In transition between RRMS and SPMS 45 (3.2%) 39 (3.4%) 6 (2.6%)
Missing/unclear 34 (2.5%) 27 (2.3%) 7 (3.0%)
Year of MS diagnosis, median (IQR) 2008
(2000; 2013)
2008
(2001; 2013)
2003
(1995; 2010)
Relationship with MS Society
Member 899 (64.8%) 714 (61.9%) 185 (79.4%)
News 224 (16.2%) 208 (18.0%) 16 (6.9%)
Other (use of SMSS services, consultations, participation in groups) 145 (10.5%) 126 (10.0%) 19 (8.2%)
No connection 98 (7.1%) 86 (7.5%) 12 (5.2%)
EQ5D domains (best 2 categories)
Pain/discomfort 878 (63.3%) 756 (65.5%) 122 (52.4%)
Mobility 896 (64.6%) 782 (67.8%) 114 (48.9%)
Ability to self-care 1231 (88.8%) 1041 (90.2%) 190 (81.6%)
Ability to perform daily activities 885 (63.8%) 775 (67.2%) 110 (47.2%)
Fear/depression 1121 (80.8%) 954 (82.7%) 167 (71.7%)
Received help with filling in questionnaire 122 (8.8%) 85 (7.4%) 37 (15.9%)
No DMT in past 6 months 564 (40.7%) 454 (39.3%) 110 (47.2%)
MS care received over past 12 months
From a neurologist 1061 (76.5%) 887 (76.9%) 174 (74.7%)
From a general practitioner 575 (41.5%) 456 (39.6%) 119 (51.1%)
At a clinic/hospital 338 (24.4%) 285 (24.7%) 53 (22.8%)
At a rehabilitation clinic 150 (10.8%) 114 (9.9%) 36 (15.5%)
Not in care with a physician / at a clinic 167 (12.0%) 136 (11.8%) 31 (13.3%)
DMT = disease-modifying treatment; MS = multiple sclerosis; IQR = interquartile range; PPMS = primary progressive MS; RRMS = elapsing-remitting MS; SPMS = secondary
progressive MS
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more years ago is not sensible. Also, the way healthcare
is organised differs substantially between countries, which
makes interpretation of differences in diagnostic and thera-
peutic pathways difficult. In addition, some countries, such
as Sweden or Denmark, have registries in which persons
with a diagnosis of MS are automatically registered either
at the time of diagnosis or at the time of treatment initiation
[16, 17]. Such enrolment mechanisms are not comparable
to those in settings such as Switzerland, where such auto-
matic registration is not foreseen. Finally, online surveys
or studies such as the UK MS Register [18] or the North
American Research Committee on Multiple Sclerosis [19],
the world’s largest MS registry, are conducted online like
the Swiss MS Registry but are not primarily longitudinal
studies.
The rapid recruitment, the diverse study population and the
high data quality demonstrate that the Swiss MS Registry
successfully leverages the advantages of traditional med-
ical research and novel approaches using societal and tech-
nological developments. Like traditional medical research,
this observational study was fully embedded within the le-
gal and ethical framework of medical research, as it ob-
tained approval from ethics committees and was based on a
fully developed protocol that described the aims, methods
and analytic approaches of the study. Thereby, the study
mitigated the risks of novel types of studies or research ef-
forts such as patientslikeme, CureTogether or studies by
Google or Facebook that have enormous potential but op-
erate in an, as yet, unclear legal and ethical framework and
may be prone to threats to internal and external validity
[8–11].
To unleash the full potential of the combination of tra-
ditional research and contemporary trends in society and
technology, digitally facilitated citizen-science studies
should adhere to the highest methodological and ethical
standards and guarantee patient rights under the Helsinki
Declaration [20]. Community outreach strengthens partic-
ipation, maximises participation diversity, and can help to
manage stakeholder expectations. Active communication
is essential for digitally facilitated citizen science. For the
Swiss MS Registry, information is spread widely through
the network of the Swiss MS Society (e.g., newsletters,
website, social media). Additionally, regular presentations
to persons with MS and clinicians, including general prac-
titioners and neurologists, raise awareness of the Swiss MS
Registry and its goals. Almost 1700 persons with MS had
enrolled in the Swiss MS Registry since its launch in June
2016, vastly exceeding expectations. We estimate that the
Swiss MS Registry currently represents around 11 to 15%
of the entire MS population in Switzerland [21, 22]. These
excellent enrolment numbers are indicative of the poten-
tial for the combination of traditional research and novel
trends.
The combination of patient-reported and clinical data, as
well as the close collaboration and possibilities for data ex-
change with the more clinically oriented Swiss MS Cohort
Study, offer possibilities not only for data validation, but
also for interesting comparisons of patient- and physician
perspectives on symptom severity or adverse drug effects,
or for investigations into patient-doctor communication as-
pects with potentially large implications for healthcare.
Although data collection has been highly standardised so
far, the Swiss MS Registry provides a basis for the collec-
tion of unstructured data from medical charts, tracking de-
vices or social media. It would have been most straight-
forward to employ existing online platforms and technolo-
gies, but these were not deemed to be safe and flexible
enough for our purpose. Therefore, we set up a new and
secure online IT infrastructure that offers flexibility to in-
corporate additional structured but also unstructured data.
Although it will take some time to collect large amounts
of data and the amount of data may never compare to on-
line platforms such as patientslikeme, our approach miti-
gates the risks of an unclear legal and ethical framework
where not only may persons affected by MS lose trust, but
researchers face many uncertainties as well. Another clear
advantage is that the source and study populations are well
known and characterised and data quality is assured.
Conclusion
The digitally facilitated citizen science approach chosen by
the Swiss MS Registry indicates a way to bridge the gap
between traditional medical research and novel approach-
es. The Swiss MS Registry is characterised by transparent
governance, operation within clear and established legal
and ethical frameworks, active community outreach and
communication, and direct involvement of persons with
MS in study planning and operation. The rapid recruitment
of a diverse study population within the first 18 months
since the inception of the Swiss MS Registry and the high
quality of the data indicate the potential of this novel con-
cept of digitally enhanced citizen science, which could be
useful for many chronic conditions. The Swiss MS Reg-
istry may therefore serve as an example for leveraging the
advantages of both traditional medical research and novel
societal and technological developments, while mitigating
their respective disadvantages and risks.
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